AKT1 and B-cell chronic lymphocytic leukemia: Due to the increased PI3K/AKT/mTOR pathway activity in CLL, studies targeting PI3K/AKT/mTOR signaling indicated pro-apoptotic effects in the treatment of CLL and other B cell leukemias (198).